AUTHORS
Kishan Patel, MD, George Goshua, MD, SM2, Jan Philipp Bewersdorf, MD3, Scott F. Huntington, MD, MPH4, Gunjan L. Shah, MD, MS5, Katya F Ahr, MD, MA6, Nigel Gwini, MD7, Varun Iyengar, MD8, Robert Stuver, MD9, Paul Hamlin, MD10, Gilles Salles I, MD, PhD11, Alison Moskowitz, MD12
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
2 Yale University, New Haven, Connecticut, United States
3 Yale University, New Haven, Connecticut, United States
4 Yale University, New Haven, Connecticut, United States
5 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
ABSTRACT
Background: The standard-of-care for fit, transplant-eligible patients with relapsed/refractory (rel/ref) classic Hodgkin lymphoma (cHL) is salvage therapy followed by consolidative high-dose chemotherapy and autologous stem cell rescue (HDT/ASCR). However, HDT/ASCR is associated with long-term toxicity including cardiopulmonary complications, sexual dysfunction, secondary malignancies, decrements in quality-of-life, and increased risk of non-relapse mortality. A recent phase II trial demonstrated that use of consolidative pembrolizumab maintenance rather than HDT/ASCR led to 3-year PFS of 54%; importantly, all patients who relapsed on maintenance were able to proceed to HDT/ASCR and achieve CR in the subsequent line of therapy (“conditional” HDT/ASCR), leading to 3-year freedom-from-third relapse of 96%. These data suggest that a substantial proportion of patients with rel/ref cHL may achieve durable remissions without “early” HDT/ASCR, and in turn may avoid the morbidity associated with HDT. In this study, we use a Markov decision-analysis model to assess both the cost-effectiveness and estimated clinical outcomes of patients with rel/ref cHL treated with “early” vs “conditional” HDT/ASCR.
Methods: We constructed a cost-effectiveness model to compare the strategy of “early” consolidative HDT/ASCR versus “conditional” consolidative HDT/ASCR in patients with rel/ref cHL. Patients entered the model with rel/ref cHL and received pembrolizumab-GVD as salvage therapy, followed by either consolidative HDT/ASCR (“early” HDT/ASCR) or pembrolizumab maintenance (“conditional” HDT/ASCR). Patients who relapsed in the “conditional” HDT/ASCR arm received BV-ICE and consolidative HDT/ASCR in the third-line setting. In both arms, a proportion of patients who relapsed after HDT/ASCR underwent allogeneic hematopoietic stem cell transplantation (allo-HCT). Monthly transition probabilities for disease progression were derived from the respective clinical trial. Transition probabilities for non-lymphoma-related death with each line of treatment were estimated by combining age-matched background mortality from US Life Tables with standardized mortality ratios (SMR) for patients with cHL pre-HDT/ASCR, post-HDT/ASCR, and post-alloHCT. The utility of each health state and the costs of treatment were derived from literature and Medicare fee schedules. We calculated the incremental cost-effectiveness ratio (ICER) of “conditional” HDT/ASCR from a US healthcare perspective, using a lifetime horizon, an annual discount rate of 3%, and a willingness-to-pay threshold of $120,000/quality-adjusted life year (QALY). One-way and probabilistic sensitivity analyses were performed to evaluate the robustness of model conclusions. In a scenario analysis, we accounted for the expected incorporation of pembrolizumab biosimilars into the market in 2028.
Results: In the base-case analysis, the use of “conditional” HDT/ASCR was associated with an incremental effectiveness of 0.13 QALYs compared with “early” HDT/ASCR (15.91 vs 15.78 QALYs, respectively) and an incremental cost of $70,515 ($387,282 vs $316,767), leading to an ICER of $553,981/QALY. The price of pembrolizumab would need to decrease by 35% (to ~$7,800 per 200mg IV dose) in order for “conditional” HDT/ASCR be cost-effective. In scenario analysis, 3 years after loss of market exclusivity, the “conditional” HDT/ASCR became the cheaper and “dominant” strategy, with an incremental cost of -$5,973 ($296,912 vs $302,885). Over a lifetime horizon, the use of “conditional” HDT/ASCR resulted in similar overall survival for patients compared to “early” HDT/ASCR (median OS of 30.3 vs 29.9 years, respectively).
Conclusion: Our Markov model offers three insights comparing “early” vs “conditional” HDT/ASCR in rel/ref cHL. First, we show that under current pricing, the use of “conditional” HDT/ASCR is not cost-effective, due primarily to the cumulative cost of pembrolizumab maintenance. Second, when we account for the introduction of pembrolizumab biosimilars, “conditional” HDT/ASCR is likely to become cost-effective compared to “early” HDT/ASCR. Lastly, in the absence of prospective data comparing these two treatment strategies, our model provides preliminary evidence that reserving HDT/ASCR until the third-line setting is unlikely to compromise overall survival for select patients with rel/ref disease.
DISCLOSURES
Kishan Patel, MD: No relevant conflicts of interest to declare.